WhiteLab Genomics raises twenty-three point two million euros to prove AI designs work in vivo
WhiteLab Genomics, a Paris-based biotechnology company that uses artificial intelligence to design genomic medicines, has closed a Series B round of twenty-three point two million euros, about twenty-six million dollars, reported in October 2026. AVP, an investment platform managing more than two point five billion euros, led the round. Yaday Health, Blast Club, Omnes Capital and Debiopharm Innovation Fund also took part.
The capital is tied to a narrow, stated goal rather than to the general excitement around artificial intelligence. Co-founder and chief executive David Del Bourgo judges success by whether designs work in living systems. The round pays for wider in vivo validation, a stronger Boston hub and a portfolio of validated bio-assets. François Robinet of AVP joins the board as the investors back that proof.
Source: EU-Startups · October 6, 2026